Capitolis Liquid Global Markets LLC Makes New Investment in Celcuity, Inc. $CELC

Capitolis Liquid Global Markets LLC acquired a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the 4th quarter, HoldingsChannel reports. The firm acquired 355,200 shares of the company’s stock, valued at approximately $35,428,000.

Several other large investors also recently bought and sold shares of CELC. Creative Planning purchased a new stake in Celcuity during the 2nd quarter worth approximately $177,000. Rhumbline Advisers increased its stake in Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares in the last quarter. XTX Topco Ltd purchased a new stake in Celcuity during the 2nd quarter worth approximately $169,000. Quantinno Capital Management LP increased its stake in Celcuity by 20.7% during the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock worth $3,245,000 after buying an additional 41,756 shares in the last quarter. Finally, Paloma Partners Management Co raised its holdings in Celcuity by 285.8% in the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock valued at $1,097,000 after acquiring an additional 60,849 shares during the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Celcuity

In other news, Director David Dalvey sold 25,000 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares of the company’s stock, valued at $9,144,200. This represents a 27.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 37,000 shares of company stock valued at $5,111,950. Corporate insiders own 13.33% of the company’s stock.

Celcuity Stock Up 0.8%

CELC stock opened at $88.05 on Thursday. The company has a market cap of $4.29 billion, a price-to-earnings ratio of -22.58 and a beta of 0.10. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity, Inc. has a 12 month low of $11.27 and a 12 month high of $151.02. The firm has a 50-day moving average of $118.29 and a two-hundred day moving average of $111.04.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. As a group, analysts forecast that Celcuity, Inc. will post -3.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings upgraded shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Wells Fargo & Company cut their price objective on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $157.00 price objective on shares of Celcuity in a report on Friday, May 15th. Craig Hallum cut their price objective on shares of Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Finally, Citizens Jmp increased their price objective on shares of Celcuity from $150.00 to $160.00 and gave the company a “market outperform” rating in a report on Monday, May 4th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and an average price target of $152.09.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.